BiotechnologyRoche receives FDA approval for VENTANA MMR RxDx Panel to identify dMMR solid tumour patients and pMMR endometrial cancer patients eligible for KEYTRUDA
Roche (SIX: RO, ROG;OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of a label expansion for the VENTANA MMR RxDx Panel. This approval advances the company’s commitment to personalised healthcare through tests that determine which patients are most likely to respond to specific and targeted therapies. The VENTANA MMR RxDx Panel is the first immunohistochemistry (IHC) companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair...